Subnavigation

• Immunization, Vaccines and Biologicals
• Strategic Advisory Group of Experts (SAGE)
• Position papers
• Global Vaccine Action Plan
• Topics
• Document centre
• Newsroom
• About us

SAGE meeting of April 2012

SalleA, CCV, Geneva, 10-12 April 2012

Presentations

Session: Report from Director, IVB

• Global report including key updates and challenges from regions
  pdf, 11.06Mb
  J.-M. Okwo-Bele

Session: Reports from other Advisory Committees on Immunization

• Report of the Global Advisory Committee on Vaccine Safety (GACVS)
  pdf, 2.19Mb
  M. Wharton, Chair of GACVS

Session: Polio eradication

• Introduction
  pdf, 1.24Mb
  B. Aylward
• Pakistan
  pdf, 2.63Mb
  S. Wazir Ali, Special Assistant to the Prime Minister/ Co-Chair Pakistan Education Task Force, Government of Pakistan
• Nigeria
  pdf, 8.54Mb
  M. Ado on behalf of . M. Pate, Honourable Minister of State for Health, Federal Ministry of Health, Abuja, Nigeria
• Afghanistan
  pdf, 819kb
  M.T. Mashal, Director General Preventive Medicine, Ministry of Public Health, Kabul, Afghanistan
• Prioritizing emergency polio eradication activities in view of the chronic financing gap
  pdf, 810kb
  H. Jafari, WHO
• The tOPV - bOPV switch and suggested IPV policy to complete type 2 eradication
  pdf, 683kb
  P. Figueroa, member of the SAGE Working Group on polio

Session: Seasonal influenza vaccine

• Global influenza burden of disease
  pdf, 804kb
  J. Bresee, member of the SAGE Working Group on influenza vaccines and immunization
• Influenza vaccine effectiveness
  pdf, 713kb
  J. Englund, member of the SAGE Working Group on influenza vaccines and immunization
• Safety of influenza vaccines
  pdf, 1.02Mb
  P. Lambach, WHO
• Presentation of recommendations
  pdf, 187kb
  A. Reingold, member of SAGE Working Group on influenza vaccines and immunization

Session: Impact of introduction of new vaccines on the strengthening of immunization and health systems

• Brief introduction to the session
  pdf, 344kb
  D. Durrheim, member of SAGE
• Summary of findings from literature reviews and assessments and interviews in the context of the WHO Health System Building Blocks Framework
  pdf, 1.51Mb
  T. Hyde, US Centers for Disease control and Prevention
• Review of findings and gaps in information on impact of new vaccines on immunization and health systems
  pdf, 401kb
  N. Arora, member of SAGE
• Principles for new vaccine introduction
  pdf, 172kb
  D. Durrheim, member of SAGE
• A practical tool for countries, updated WHO document entitled: "Principles and Considerations for Adding a Vaccine to a National Immunization Programme”
  pdf, 2.51Mb
  S. Wang, WHO

Session: Vaccination in humanitarian emergencies

• Brief introduction of the process that is being followed for the development of the framework
  pdf, 62kb
  H. Rees, Chair of SAGE Working Group on vaccination in humanitarian emergencies
• Literature review of vaccination experience in previous humanitarian emergencies /Existing recommendations and guidance
  pdf, 174kb
  Z. Bhutta, member of the SAGE Working Group on vaccination in humanitarian emergencies
• Ethical issues surrounding use of vaccines in emergency settings
  pdf, 65kb
  K. Moodley, member of the SAGE Working Group on vaccination in humanitarian emergencies
• Vaccination in acute humanitarian emergencies: a framework for decision-making
  pdf, 324kb
  R. Waldman, member of the SAGE working group on use of vaccination in humanitarian emergencies

Session: Rotavirus vaccines schedules

• Optimizing rotavirus schedules: what are the key questions for today's session?
  pdf, 6.27Mb
  P. Fine, London School of Hygiene and Tropical Medicine
• Rotavirus vaccine effectiveness after 2 or 3 doses and risk of Intussusception after rotavirus vaccination
  pdf, 474kb
  U. Parashar, US Centres for Disease Control and Prevention
• Rotavirus vaccination: tailoring the immunization schedule to the local epidemiology and operational realities
  pdf, 888kb
  C. Sanderson, London School of Hygiene and Tropical Medicine
• Benefits of mortality reduction versus risk of fatal intussusception
  pdf, 6.65Mb
  M. Patel, US Centres for Disease Control and Prevention
• Overview of major conclusions from the ad hoc group of experts
  pdf, 1.99Mb
  J. Abramson, member of SAGE

Session: Use of hepatitis A vaccines

• Impact and monitoring the impact of single dose hepatitis A vaccine use in Argentina
  pdf, 2.22Mb
  C. Vizzotti, Ministry of Health, Argentina
• Process of evidence and data collection and overview of evidence obtained including GRADE tables
  pdf, 1.14Mb
  D. Shouval, Hadassah Hebrew University Hospital, Israel
• Draft recommendations for flexible use of inactivated hepatitis A vaccine booster dose
  pdf, 61kb
  A. Reingold, Chair of SAGE working group on hepatitis A

Session: Report from the GAVI Alliance Secretariat

• Report from GAVI Alliance
  pdf, 7.38Mb
  S. Berkley, GAVI Alliance

Session: Information on vaccines for an Intergovernmental Negotiating Committee on Mercury

• Outcomes from a WHO Informal Consultation (3-4 April) on further guidance on vaccines in preparation for the fourth Intergovernmental Negotiating Committee (INC4)
  E. Griffiths
• Perspectives from stakeholders countries
  pdf, 1.56Mb
  C. Ruiz-Matus, WHO
• Manufacturers perspective, S. Jadhav, Developing Countries Vaccine Manufacturers Network
  pdf, 194kb
  S. Jadhav, Developing Countries Vaccine Manufacturers Network
• Potential guidance to countries on vaccines for the mercury-treaty negotiations
  pdf, 548kb
  D. Wood, WHO